Array BioPharma, Inc. has initiated dosing in a Phase I trial with ARRY-520, a targeted small molecule anticancer drug. ARRY-520 is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human cancer at tolerated doses, often leading to complete, durable responses. The Phase I open-label, dose-escalation trial is designed to evaluate the safety, tolerability and pharmacokinetics of ARRY-520 following intravenous administration to patien...